Companies / Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

NasdaqCIK 1766140MOUNTAIN VIEW, CA

Financials · FY2023

Revenue$675.0K
Net income$-26.55M
Total debt—
Cash$44.19M
Diluted EPS$-1.67
Shares outstanding27.9M

Ownership

27.9M shares outstanding · as of Aug 12, 2026
3.6%10%+ / strategic
Ownership
10%+ / strategic3.59%1,000,000
Institutions34.35%9,568,417
Public float62.06%17,286,840

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 0

View all →
Insider% of sharesShares
No insiders recorded yet.

Institutional holders 41

View all →
HolderValue% of shares
Vivo Capital, LLC$10.33M6.43%
Millennium Management LLC$9.21M5.02%
BlackRock, Inc.$6.63M5.07%
Octagon Capital Advisors LP$5.77M3.59%
Nantahala Capital Management, LLC$5.42M3.37%
Great Point Partners, LLC$5.24M2.86%
Vanguard Group Inc$4.55M2.83%
Logos Global Management LP$2.73M1.70%
State Street Corporation$2.11M1.62%
Citadel Advisors LLC$1.49M0.93%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
No activity matches these filters.

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Integrated Core Strategies (US) LLCPassive13G———
RA Capital Management, L.P.Passive13G/A———
Nantahala Capital Management, LLCPassive13G/A———
Octagon Capital Advisors LPPassive13G/A—1,000,000—
RA Capital Management, L.P.Passive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
———90466Y202—